SCHEMBL7992010

SCHEMBL7992010

COCCOCCOc1ccc(C=O)cc1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.56
MAPT P10636 3/20 0.56
HPGD P15428 3/20 0.56
LMNA P02545 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
KDM4E B2RXH2 1/20 0.53
RECQL P46063 1/20 0.53
CYP2A6 P11509 1/20 0.52
FDPS P14324 1/20 0.45
APP P05067 1/20 0.44
ALDH1A3 P47895 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3210160 1.00 ALDH1A1 (0.56) ALDH1A1MAPTHPGDLMNASMN1; SMN2
SCHEMBL3211688 1.00 ALDH1A1 (0.56) ALDH1A1MAPTHPGDLMNASMN1; SMN2
SCHEMBL246323 0.94 ALDH1A1 (0.61) ALDH1A1MAPTHPGDLMNASMN1; SMN2
SCHEMBL8371513 0.91 ALDH1A1 (0.59) ALDH1A1MAPTHPGDLMNASMN1; SMN2
SCHEMBL1524953 0.89 ALDH1A1 (0.52) ALDH1A1MAPTHPGDLMNASMN1; SMN2
SCHEMBL3683901 0.86 ALDH1A1 (0.60) ALDH1A1MAPTHPGDLMNASMN1; SMN2
SCHEMBL27029040 0.86 ALDH1A1 (0.60) ALDH1A1MAPTHPGDLMNASMN1; SMN2
SCHEMBL9484385 0.86 ALDH1A1 (0.60) ALDH1A1MAPTHPGDLMNASMN1; SMN2
SCHEMBL10069015 0.85 APP (0.58) ALDH1A1MAPTHPGDKDM4ERECQL
SCHEMBL3720061 0.85 ALDH1A1 (0.69) ALDH1A1MAPTHPGDLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220106327-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-07 US disclosed
US-10851302-B2 Metal organic liquid crystal dyes GAUZY LTD. (IL) 2020-12-01 US disclosed
EP-3209748-B1 METAL ORGANIC LIQUID CRYSTAL DYES GAUZY LTD (IL) 2020-05-06 EP disclosed
US-20170355908-A1 METAL ORGANIC LIQUID CRYSTAL DYES GAUZY LTD. (IL) 2017-12-14 US disclosed
US-20170355908-A1 METAL ORGANIC LIQUID CRYSTAL DYES GAUZY LTD. (IL) 2017-12-14 US disclosed
EP-3209748-A1 METAL ORGANIC LIQUID CRYSTAL DYES Gauzy Ltd (IL) 2017-08-30 EP disclosed
US-6288061-B1 INTERLEUKIN INHIBITORS; ASTHMA, BRONCHODILATOR AGENTS, ANTIALLERGENS WELFIDE CORPORATION (JP) 2001-09-11 US disclosed
US-5686610-A Pyridyl piperazine compound PHARMACIA & UPJOHN COMPANY (US) 1997-11-11 US disclosed
EP-0485636-B1 INDOLE DERIVATIVE TORAY INDUSTRIES (JP) 1997-03-12 EP disclosed
US-5599930-A Substituted indoles as anti-AIDS pharmaceuticals THE UPJOHN COMPANY (US) 1997-02-04 US disclosed
EP-0594702-B1 SUBSTITUTED INDOLES AS ANTI-AIDS PHARMACEUTICALS UPJOHN CO (US) 1997-01-29 EP disclosed
EP-0735026-A1 Method for the production of isoquinoline derivatives and their use as intermediates in the preparation of indole derivatives TORAY INDUSTRIES, INC. (JP) 1996-10-02 EP disclosed
US-5539119-A MULTISTAGE FORMATION BY OXIDATION, REDUCING A CARBAMATE TO FORM AN ENAMINE, FORMING AN OXIDE TORAY INDUSTRIES, INC. (JP) 1996-07-23 US disclosed
EP-0594702-A1 SUBSTITUTED INDOLES AS ANTI-AIDS PHARMACEUTICALS. UPJOHN CO (US) 1994-05-04 EP disclosed
US-5244904-A Immunorepressant, analgesic TORAY INDUSTRIES, INC. (JP) 1993-09-14 US disclosed
WO-1993001181-A1 SUBSTITUTED INDOLES AS ANTI-AIDS PHARMACEUTICALS THE UPJOHN COMPANY (US) 1993-01-21 WO disclosed
EP-0485636-A1 INDOLE DERIVATIVE TORAY INDUSTRIES, INC. (JP) 1992-05-20 EP disclosed
EP-0150952-B1 PHOTOPOLYMERIZABLE COMPOSITION KURARAY CO., LTD. (JP) 1989-08-30 EP disclosed
US-4668712-A MONOMER, PHOTOINITIATOR, DENTAL FILLINGS KURARAY CO., LTD. (JP) 1987-05-26 US disclosed
EP-0150952-A2 Photopolymerizable composition KURARAY CO., LTD. (JP) 1985-08-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220106327-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME APOL1, PNLIP, APOB ALDH1A1 3889/4885MAPT 384/4885HPGD 2560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.